Positive revenue and earnings trend – further growth in recurring revenue
The Medical Technology Business Group of ZEISS continues to strengthen its leadership team with the appointment of distinguished refractive surgeon and clinical professor of ophthalmology, Steven C. Schallhorn, MD as Chief Medical Officer for Global Ophthalmic Devices. The appointment of Dr. Schallhorn supports ZEISS’ commitment to advancing eye care and helping doctors bring the highest level of clinical care to their patients around the world.
The Medical Technology Business Group of ZEISS announces the introduction in the US of the VisuMax
Revenue, EBIT and earnings per share show positive development
Carl Zeiss Meditec AG consolidates its ophthalmology activities in a single Strategic Business Unit; James V. Mazzo will head the new ophthalmology division.
Publication of the Annual Financial Statements 2015/16 and Analyst Conference
3 Month 2016/17 Publication - Conference Call
Annual General Meeting, Weimar, Germany
6 Month 2016/17 Publication - Conference Call
9 Month 2016/17 Publication - Conference Call
Publication of the Annual Financial Statements 2016/17 and Analyst Conference
Be informed about the performance, key facts and the shareholder structure.
We welcome you to Carl Zeiss Meditec AG's Investor Relations website and thank you for your interest in our company.
To ensure the highest possible level of transparency, this website provides comprehensive and detailed information on our IR activities and the performance of the Carl Zeiss Meditec Group. This website is especially tailored for the dialogue with institutional investors, financial analysts and private shareholders as well as anyone interested in our financial performance.
Here you can find the latest presentations, the reports of the current fiscal year, ad hoc announcements as well as all important facts and figures about the company's financial situation.